89IN - Skin toxicity

Date 27 September 2014
Event ESMO 2014
Session Targeting precision medicine toxicity
Topics Complications/Toxicities of Treatment
Supportive Measures
Presenter Caroline Robert
Citation Annals of Oncology (2014) 25 (suppl_4): iv33-iv34. 10.1093/annonc/mdu310
Authors C. Robert
  • Dermatology, Institut Gustave Roussy, - - Villejuif/FR




The skin is unfortunately one of the major target of our so-called targeted agents which are associated with numerous and diverse adverse events. Some skin manifestation are mild and can be considered as “associated events” that do not need any specific management, however some events are more concerning, sometimes impairing patients' quality of life or raising safety issues like the skin tumors emerging with BRFA inhibitors. The impact on the patients' quality of life always need to be evaluated and is not always in direct relation with the intensity of the symptoms. Patients and physicians must be informed and educated on the entire spectrum of skin and mucosal adverse events that can occur with the use of targeted agents and on the way to prevent them, to limit their intensity and to manage them when they are present. Adequate reporting of all skin adverse events occurring during the course of targeted therapies, as well as performing studies aiming at understanding the mechanisms underlying these eventsis are keys to treat these symptoms in an optimal and comprehensive way.


C. Robert: Consultant for Roche, BMS, GSK, Novartis, Amgen, Merck